National trends in surgical procedures for hepatocellular carcinoma: 1998-2008
- PMID: 22009384
- DOI: 10.1002/cncr.26501
National trends in surgical procedures for hepatocellular carcinoma: 1998-2008
Abstract
Background: The incidence of hepatocellular carcinoma (HCC) is rising, and the options for surgical therapy of HCC have evolved recently, but use of surgical therapy has not been characterized on a representative, nationwide basis. We quantified trends in use, mortality, and patient and hospital characteristics for 3 surgical therapies for HCC (resection, ablation, and transplantation) in the United States from 1998 to 2008.
Methods: Hospital discharge data from the Nationwide Inpatient Sample were used to quantify procedure-related data for each year. Trends over time were summarized as the average annual percent change (AAPC) and corresponding 95% confidence interval (CI).
Results: The number of surgical procedures for HCC increased from 1416 to 6769 (AAPC, 13.5%; 95% CI, 10.2%-16.8%). Volumes increased for all surgical procedures, most notably for ablation (AAPC, 17.3%; 95% CI, 6.6%-29.2%) and transplantation (AAPC, 20.9%; 95% CI, 14.1%-28.1%). When analyzed as a proportion of total procedures, there were declines in the relative use of major hepatectomy (35% to 16%; AAPC, -7.2%, 95% CI, -8.8% to -5.6%) and wedge resection (37% to 22%; AAPC, -4.8%; 95% CI, -6.2% to -3.4%), while the proportion accounted for by transplantation increased (16% to 35%; AAPC, 4.4%; 95% CI, 0.2%-8.9%). Inpatient mortality decreased for each procedure individually and overall from 7.3% to 4.6% (AAPC, -7.7%; 95% CI, -10.8% to -4.5%), despite increasing age and comorbidity burden.
Conclusions: The use of surgical therapy for HCC has increased dramatically over the last decade, with a relative shift away from liver resection and toward liver transplantation. These therapeutic modalities must be better targeted to make the most appropriate use of limited health care resources.
Copyright © 2011 American Cancer Society.
Similar articles
-
Volumes of liver transplant and partial hepatectomy procedures are independently associated with lower postoperative mortality following resection for hepatocellular carcinoma.Liver Transpl. 2009 Jul;15(7):776-81. doi: 10.1002/lt.21767. Liver Transpl. 2009. PMID: 19562711
-
In-hospital mortality from liver resection for hepatocellular carcinoma: a simple risk score.Cancer. 2010 Apr 1;116(7):1733-8. doi: 10.1002/cncr.24904. Cancer. 2010. PMID: 20143433
-
Liver transplantation for hepatocellular carcinoma: past, present, and future.Clin Transpl. 2012:173-83. Clin Transpl. 2012. PMID: 23721020 Review.
-
Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population.Am J Surg. 2008 Jun;195(6):829-36. doi: 10.1016/j.amjsurg.2007.10.010. Epub 2008 Apr 23. Am J Surg. 2008. PMID: 18436176 Review.
-
National trends in the use of surgery for benign hepatic tumors in the United States.Surgery. 2015 Jun;157(6):1055-64. doi: 10.1016/j.surg.2015.01.015. Epub 2015 Mar 11. Surgery. 2015. PMID: 25769697 Free PMC article.
Cited by
-
A multicentre, randomized clinical trial comparing the Veriset™ haemostatic patch with fibrin sealant for the management of bleeding during hepatic surgery.HPB (Oxford). 2013 Jul;15(7):548-58. doi: 10.1111/hpb.12009. Epub 2012 Dec 27. HPB (Oxford). 2013. PMID: 23458162 Free PMC article. Clinical Trial.
-
Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review.J Gastrointest Surg. 2014 Dec;18(12):2136-48. doi: 10.1007/s11605-014-2667-1. Epub 2014 Oct 10. J Gastrointest Surg. 2014. PMID: 25300798
-
Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study.PLoS One. 2019 Aug 26;14(8):e0221614. doi: 10.1371/journal.pone.0221614. eCollection 2019. PLoS One. 2019. PMID: 31449554 Free PMC article.
-
Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis.Ann Surg. 2013 Dec;258(6):1022-7. doi: 10.1097/SLA.0b013e31827da749. Ann Surg. 2013. PMID: 23299519 Free PMC article.
-
Obesity and recurrence-free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C.Ann Gastroenterol Surg. 2018 Jun 22;2(4):319-326. doi: 10.1002/ags3.12183. eCollection 2018 Jul. Ann Gastroenterol Surg. 2018. PMID: 30003195 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical